scispace - formally typeset
J

Jeremy J. Erasmus

Researcher at Duke University

Publications -  110
Citations -  7077

Jeremy J. Erasmus is an academic researcher from Duke University. The author has contributed to research in topics: Lung cancer & Positron emission tomography. The author has an hindex of 37, co-authored 110 publications receiving 6514 citations. Previous affiliations of Jeremy J. Erasmus include University of Texas MD Anderson Cancer Center & University of Texas System.

Papers
More filters
Journal ArticleDOI

The BATTLE Trial: Personalizing Therapy for Lung Cancer

TL;DR: The BATTLE study is the first completed prospective, adaptively randomized study in heavily pretreated NSCLC patients that mandated tumor profiling with "real-time" biopsies, taking a substantial step toward realizing personalized lung cancer therapy by integrating real-time molecular laboratory findings.
Journal ArticleDOI

Solitary pulmonary nodules: Part I. Morphologic evaluation for differentiation of benign and malignant lesions.

TL;DR: Evaluation of specific morphologic features of a solitary pulmonary nodule with conventional imaging techniques can help differentiate benign from malignant nodules and obviate further costly assessment.
Journal ArticleDOI

Pulmonary Drug Toxicity: Radiologic and Pathologic Manifestations

TL;DR: Pulmonary drug toxicity is increasingly being diagnosed as a cause of acute and chronic lung disease and knowledge of these manifestations and of the drugs most frequently involved can facilitate diagnosis and institution of appropriate treatment.
Journal ArticleDOI

Evaluation of primary pulmonary carcinoid tumors using FDG PET

TL;DR: On FDG PET imaging, pulmonary carcinoid tumors usually have lower FDG uptake than expected for malignant tumors, and biopsy or close radiologic follow-up is recommended for solitary pulmonary nodules that are clinically suspected of being carcinoid tumor and that do not show increased metabolic activity onFDG PET images.
Journal ArticleDOI

Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.

TL;DR: PET with FDG is an accurate, noninvasive way to differentiate benign from metastatic adrenal masses in patients with bronchogenic carcinoma.